PharmEasy

How it happened

PharmEasy is an Indian online pharmacy and healthtech platform that peaked at roughly $5.6B in 2021 after rapid pandemic-era growth and acquisitions. Mounting losses and debt forced a heavily discounted rights issue and steep investor markdowns; Neuberger Berman cut its stake to imply a valuation near $456M by late 2024, a fall of about 92% from peak. Glassdoor reviews from the 2022-23 cash crunch describe the strain from inside: recurring layoff rounds that some staff said arrived every few months, pervasive job insecurity that employees tied directly to the company's finances, and frozen hikes with stock options worth far less than promised.

Employee accounts paraphrase anonymous, unverified reviews posted publicly on Glassdoor ↗. See our methodology.